<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022616</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-09142</org_study_id>
    <nct_id>NCT04022616</nct_id>
  </id_info>
  <brief_title>Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients</brief_title>
  <official_title>Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2010</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Isolate unfavorable immune cells MDSC from the peripheral blood or tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells.</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies.
isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood or the tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells. Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood of study subjects who plan to start pre-operative chemotherapy for breast cancer to see if MDSC levels can predict who will respond to treatment. W</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Percentage of MDSC at baseline and whether there is an association of baseline MDSC percent with response to chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isolate unfavorable immune cells MDSC from peripheral blood of study subjects who receive pre-operative chemotherapy for breast cancer to identify changes in MDSC levels during treatment can predict who will respond to treatment.</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Changes will be reported in percentage of MDSC and associations of such changes with response to chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isolate lymph nodes from patients with breast cancer undergoing breast surgery to study what types of Natural Killer Cells are present.</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Isolate a lymph nodes from patients with breast cancer undergoing breast surgery to study what types of Natural Killer Cells are present. Natural Killer cells are immune cells that are capable of killing cancer cells.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <description>Adult patients with breast malignancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neo-adjuvant Chemotherapy</arm_group_label>
    <description>Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymph Node Tissue</arm_group_label>
    <description>Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Breast Cancer</arm_group_label>
    <description>Adult patients with biopsy proven stage IV breast cancer who are starting a new line palliative systemic therapy. A palliative systemic therapy will be defined in this trial as any chemotherapy regimen or combination of endocrine therapy with targeted agents such as cyclin dependent kinase 4/6 (CDK 4/6) inhibitors, HER2 targeting agents or inhibitors of mammalian target of rapamycin (mTOR).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specimen collection</intervention_name>
    <description>Specimens are obtained from patients who are being treated for breast malignancies.</description>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <arm_group_label>Lymph Node Tissue</arm_group_label>
    <arm_group_label>Metastatic Breast Cancer</arm_group_label>
    <arm_group_label>Neo-adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are being treated at the Ohio State Comprehensive Cancer Center and Stefanie
        Spielman Comprehensive Breast Center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Ability to give informed consent

          -  Stage I-III breast malignancy

        Exclusion Criteria:

          -  Unable to tolerate venipuncture
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Carson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohio State Comprehensive Cancer Center</last_name>
    <phone>1-800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>William Carson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

